New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareLivagen vs Tirzepatide

Livagen vs Tirzepatide

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Livagen
GLP-1 / Weight Loss Agonists
Tirzepatide
Summary
Livagen is a dipeptide bioregulator (Lys-Glu) developed by Professor Vladimir Khavinson, tissue-specific for the liver and thymus. It supports hepatocyte function, promotes liver cell regeneration, and modulates immune function via thymic activity. Research suggests benefits in chronic liver disease, hepatic aging, and immune restoration following liver damage.
Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist that produces greater weight loss than semaglutide in head-to-head trials. SURMOUNT-1 trial showed average 21% body weight reduction at 72 weeks at the highest dose. Marketed as Mounjaro (diabetes) and Zepbound (obesity).
Half-Life
Short (minutes); gene-regulatory effects are sustained
~5 days
Admin Route
SubQ, Oral
SubQ
Research
Typical Dose
10 mg per day
2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg
Frequency
Daily for 10–30 days
Once weekly, subcutaneous
Key Benefits
  • Supports hepatocyte regeneration and liver tissue repair
  • Normalizes liver cell protein synthesis
  • Immune modulation via thymic activity
  • Potential benefits in chronic hepatitis and liver aging
  • Anti-aging effects on hepatic tissue
  • May support liver recovery after toxic insult or alcohol damage
  • Complementary to NAD+ and glutathione in liver health protocols
  • Average 21% body weight reduction at highest dose (SURMOUNT-1)
  • Superior to semaglutide in head-to-head SURPASS trials
  • Dual GIP/GLP-1 mechanism for enhanced metabolic control
  • Significant reduction in HbA1c for type 2 diabetes
  • Improved cardiovascular risk markers
  • Reduces visceral fat preferentially
  • FDA-approved for T2DM (Mounjaro) and obesity (Zepbound)
  • Weekly dosing
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant hepatotoxic effects reported at standard doses
  • Nausea (most common during titration)
  • Vomiting
  • Diarrhea or constipation
  • Abdominal pain
  • +3 more
Stacks With